Daina Graybosch

Yigal Nochomovitz

Jonathan Miller

Peter Lawson

Asthika Goonewardene

Eva Fortea-Verdejo

Jason Zemansky

Li Wang Watsek

Salveen Richter

Emily Bodnar

Karina Rabayeva

Kaveri Pohlman

Li Watsek

Terence Flynn

Umer Raffat

- Arcus Biosciences is in a **transformational period** with **four molecules** in late-stage (Phase 3) programs, including **Casdatafan**, **DomZim**, and **Quemly**, targeting major markets.  **[1724521_tx_377881_1]** **[1724521_tx_377881_2]** 
- For **Casdatafan**, an investor event is scheduled for **October 6** to share updated monotherapy data, including the first look at **progression-free survival (PFS)** data.  **[1724521_tx_377881_1]**  The company has initiated two Phase 3 studies: Peak One (Casdatafan plus cabo) and a collaboration with AstraZeneca (Casdatafan plus Volru), with Peak One expected to enroll in less than **18 months**.  **[1724521_tx_377881_1]** **[1724521_tx_377881_5]** 
- The Phase 3 study for **DomZim** (Start 221 in upper GI cancers) is expected to read out in **2026**  **[1724521_tx_377881_1]** , having been fully enrolled in **June 2024**.  **[1724521_tx_377881_10]**  Data from its Phase 2 correlate, Edge Gastric, including **overall survival (OS)**, will be presented at ESMO.  **[1724521_tx_377881_1]** 
- The Phase 3 study for **Quemly** in pancreatic cancer is fully enrolled as of **September 2025**, having completed enrollment in approximately **nine months**, significantly ahead of schedule, with a readout anticipated in the next **12 to 18 months**.  **[1724521_tx_377881_1]** **[1724521_tx_377881_11]**

Arcus Biosciences Provides Updates on Late-Stage Clinical Programs and Upcoming Data Readouts

Arcus Biosciences (RCUS)